Trial reportDiabetes2014
Sitagliptin, a DPP-4 inhibitor, acutely inhibits intestinal lipoprotein particle secretion in healthy humans.
Trial report in Diabetes, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01600703 (Sitagliptin), which is not on this map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Sitagliptin (®Januvia) Regulation of Intestinal and Hepatic Lipoprotein Particle and Hepatic Glucose Production in Humans
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 70 citations in OpenAlex.
- Effects of Sitagliptin on Metabolic Indices and Hormone Levels in Polycystic Ovary Syndrome: a Meta-analysis of Randomized Controlled Trials.Reproductive sciences (Thousand Oaks, Calif.) · 2023Pooled it
- Gut-derived lipopolysaccharides increase post-prandial oxidative stress via Nox2 activation in patients with impaired fasting glucose tolerance: effect of extra-virgin olive oil.European journal of nutrition · 2019Trial
- Trial
- Minor Contribution of Endogenous GLP-1 and GLP-2 to Postprandial Lipemia in Obese Men.PloS one · 2016Trial
- Glucagon-like peptide-2 regulates release of chylomicrons from the intestine.Gastroenterology · 2014Trial
- Article
- From worms to humans: Understanding intestinal lipid metabolism via model organisms.Biochimica et biophysica acta. Molecular and cell biology of lipids · 2023Review
- A bibliometric analysis and visualization of literature on non-fasting lipid research from 2012 to 2022.Frontiers in endocrinology · 2023Article
- GLP-1 and GLP-2 Orchestrate Intestine Integrity, Gut Microbiota, and Immune System Crosstalk.Microorganisms · 2022Review
- Intestinal lipid absorption and transport in type 2 diabetes.Diabetologia · 2022Review
- A novel chicken model of fatty liver disease induced by high cholesterol and low choline diets.Poultry science · 2021Article
- Enteroendocrine Hormone Secretion and Metabolic Control: Importance of the Region of the Gut Stimulation.Pharmaceutics · 2020Review
- Hematopoietic cell- versus enterocyte-derived dipeptidyl peptidase-4 differentially regulates triglyceride excursion in mice.JCI insight · 2020Article
- Repurposing Antidiabetic Drugs for Cardiovascular Disease.Frontiers in physiology · 2020Review
- Exercise and the dipeptidyl-peptidase IV inhibitor sitagliptin do not improve beta-cell function and glucose homeostasis in long-lasting type 1 diabetes-A randomised open-label study.Endocrinology, diabetes & metabolism · 2019Article
- Lactobacillus mucosae DPC 6426 as a bile-modifying and immunomodulatory microbe.BMC microbiology · 2019Article
- Clinical Use of DPP-4 Inhibitors.Frontiers in endocrinology · 2019Review
- Recombinant Incretin-Secreting Microbe Improves Metabolic Dysfunction in High-Fat Diet Fed Rodents.Scientific reports · 2017Article
- Article
- The regulatory role of DPP4 in atherosclerotic disease.Cardiovascular diabetology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
The dipeptidyl peptidase-4 inhibitor sitagliptin, an antidiabetic agent, which lowers blood glucose levels, also reduces postprandial lipid excursion after a mixed meal. The underlying mechanism of this effect, however, is not clear. This study examined the production and clearance of triglyceride-rich lipoprotein particles from the liver and intestine in healthy volunteers in response to a single oral dose of sitagliptin. Using stable isotope tracer techniques and with control of pancreatic hormone levels, the kinetics of lipoprotein particles of intestinal and hepatic origin were measured. Compared with placebo, sitagliptin decreased intestinal lipoprotein concentration by inhibiting particle production, independent of changes in pancreatic hormones, and circulating levels of glucose and free fatty acids. Fractional clearance of particles of both intestinal and hepatic origin, and production of particles of hepatic origin, were not affected. This pleiotropic effect of sitagliptin may explain the reduction in postprandial lipemia seen in clinical trials of this agent and may provide metabolic benefits beyond lowering of glucose levels.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.